If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, involved bone marrow, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Samples submitted under a COG protocol can also be used in many cases for this test (some COG-banked samples may require approval from the study chair to be used for this test). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to assess % tumor content in the sample.

Fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides must contain minimum of ≥10% tumor content, while bone marrow requires ≥30% tumor content. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue, paraffin-embedded tissue, or bone marrow at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test.

This test is a FISH analysis performed on tumor specimens and identifies amplification of the MYCN (N-MYC) oncogene locus. Presence or absence of MYCN amplification may be used to help assign risk classification for neuroblastoma.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors, including age at time of diagnosis, INSS staging, MYCN amplification status, DNA Ploidy, and Shimada histology. 

References: Pinto NR et al (2015). Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 33:3008-17; Foussel MF and Robinson GW (2013).

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, involved bone marrow, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Samples submitted under a COG protocol can also be used in many cases for this test (some COG-banked samples may require approval from the study chair to be used for this test). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to assess % tumor content in the sample.

Fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides must contain minimum of ≥10% tumor content, while bone marrow requires ≥30% tumor content. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue, paraffin-embedded tissue, or bone marrow at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test.

This test is a FISH analysis performed on tumor specimens and identifies amplification of the MYCN (N-MYC) oncogene locus. Presence or absence of MYCN amplification may be used to help assign risk classification for neuroblastoma.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors, including age at time of diagnosis, INSS staging, MYCN amplification status, DNA Ploidy, and Shimada histology. 

References: Pinto NR et al (2015). Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 33:3008-17; Foussel MF and Robinson GW (2013).

This test is a FISH analysis performed on tumor specimens and identifies amplification of the MYCN (N-MYC) oncogene locus. Presence or absence of MYCN amplification may be used to help assign risk classification for neuroblastoma.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors, including age at time of diagnosis, INSS staging, MYCN amplification status, DNA Ploidy, and Shimada histology. 

References: Pinto NR et al (2015). Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 33:3008-17; Foussel MF and Robinson GW (2013).

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, involved bone marrow, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Samples submitted under a COG protocol can also be used in many cases for this test (some COG-banked samples may require approval from the study chair to be used for this test). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to assess % tumor content in the sample.

Fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides must contain minimum of ≥10% tumor content, while bone marrow requires ≥30% tumor content. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue, paraffin-embedded tissue, or bone marrow at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test.

This test is a FISH analysis performed on tumor specimens and identifies amplification of the MYCN (N-MYC) oncogene locus. Presence or absence of MYCN amplification may be used to help assign risk classification for neuroblastoma.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors, including age at time of diagnosis, INSS staging, MYCN amplification status, DNA Ploidy, and Shimada histology. 

References: Pinto NR et al (2015). Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 33:3008-17; Foussel MF and Robinson GW (2013).